Merck Entered into a Definitive Agreement to Acquire Imago BioSciences for ~$1.35B
Shots:
- Merck to acquire Imago for $36.00/share in cash for a total equity value of $1.35B. The transaction is expected to close in Q1’23
- The acquisition will use Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat for patients with myeloproliferative neoplasms. The acquisition also strengthens Merck’s growing hematology portfolio
- Additionally, Imago’s bomedemstat (IMG-7289) is an orally available LSD1 inhibitor & is currently being studied in multiple P-II clinical trials for essential thrombocythemia (ET), MF, and PV along with other indications
Ref: Merck | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
